Venrock Healthcare Capital Partners and affiliates acquire 11.9% stake in Lycia Therapeutics, signaling investor confidence in the biological products sector.
| Name | Lycia Therapeutics, Inc. |
|---|---|
| CIK | 0001806540 |
| Tickers | LYCA |
| Exchanges | Nasdaq |
| Entity type | other |
| Category | — |
| SIC | 2836 Biological Products, (No Diagnostic Substances) |
| EIN | 843860514 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | (650) 392-3357 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Venrock Healthcare Capital Partners and affiliates acquire 11.9% stake in Lycia Therapeutics, signaling investor confidence in the biological products sector.
Lycia Therapeutics' CEO Aetna Wun Trombley reports a significant stock option transaction, signaling a strategic move for the company in the biological products industry.
Lycia Therapeutics' director William J.L. Rieflin reports significant stock option transactions, signaling confidence in the company's future.
Lycia Therapeutics has granted stock options to director Jane Henderson, emphasizing its commitment to talent retention in the biological products sector.
Lycia Therapeutics, Inc. discloses stock option transactions by director Fischer Laurent, emphasizing executive retention strategies in the biological products sector.
Lycia Therapeutics has amended its articles of incorporation and bylaws following its IPO, signaling a strategic shift in the biological products sector.
Lycia Therapeutics has filed a prospectus to raise capital, signaling growth strategies in the biological products sector.
Lycia Therapeutics has received a notice of effectiveness for its recent filing, marking a significant step for the company and the biological products industry.
Lycia Therapeutics files registration statement for employee stock plans, signaling commitment to growth and talent retention in the biological products sector.
Lycia Therapeutics receives approval for its securities listing, a significant milestone for the company and the biological products industry.
Lycia Therapeutics has registered to sell an additional 3.38 million shares of common stock, signaling growth potential in the biological products sector.
Eli Lilly & Co. acquires a significant stake in Lycia Therapeutics, signaling a strategic partnership in the biological products sector.
Lycia Therapeutics has filed a new ownership report indicating a stock option grant for director Jane Henderson, reflecting ongoing executive incentives.
Lycia Therapeutics, Inc. announces changes in ownership structure, impacting its position in the biological products sector.
Lycia Therapeutics reveals significant ownership changes by director William J. Rieflin, impacting its governance and the biological products industry.
Lycia Therapeutics updates SEC filing, revealing key ownership changes involving Aetna Wun Trombley, signaling potential strategic shifts.
Lycia Therapeutics reports a significant ownership change as Carolyn Bertozzi files a Form 3, indicating potential shifts in strategy within the biological products sector.
Lycia Therapeutics, Inc. has filed to register its common stock on Nasdaq, signaling growth in the biological products sector.
Lycia Therapeutics has filed an amended registration statement for its IPO, planning to offer 14.7 million shares priced between $16 and $18.
Lycia Therapeutics, Inc. files S-1 registration statement, advancing toward a public offering in the competitive biological products sector.
40 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-04 | 4 | xslF345X06/form4-11042026_101140.xml | 0001231919-26-001536 | 22088 | ||||||
| 2026-10-30 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001738048-26-000077 | 005-95988 | 261509527 | 34 | 38982 | |||
| 2026-10-30 | 4 | xslF345X06/form4-10302026_111001.xml | 0001231919-26-001519 | 32467 | ||||||
| 2026-10-28 | 4 | 4 | 0001193125-26-436415 | 21450 | ||||||
| 2026-10-27 | 4 | xslF345X06/form4-10272026_101057.xml | 0001231919-26-001503 | 41899 | ||||||
| 2026-10-26 | 4 | xslF345X06/form4-10262026_111023.xml | 0001379344-26-000011 | 8304 | ||||||
| 2026-10-26 | 4 | xslF345X06/form4-10262026_111054.xml | 0001422304-26-000005 | 8302 | ||||||
| 2026-10-26 | 4 | xslF345X06/form4-10262026_111031.xml | 0001182471-26-000007 | 8318 | ||||||
| 2026-10-26 | 4 | xslF345X06/form4-10262026_111001.xml | 0002159567-26-000005 | 6027 | ||||||
| 2026-10-26 | 4 | xslF345X06/form4-10262026_111030.xml | 0002159565-26-000005 | 6033 | ||||||
| 2026-10-26 | 4 | xslF345X06/form4-10262026_111002.xml | 0002010805-26-000007 | 5975 | ||||||
| 2026-10-26 | 4 | xslF345X06/form4-10262026_101015.xml | 0002050422-26-000017 | 6028 | ||||||
| 2026-10-26 | 4 | xslF345X06/form4-10262026_101023.xml | 0001750495-26-000007 | 5984 | ||||||
| 2026-10-26 | 8-K | 8-K | 5.03,9.01 | 0001628280-26-067312 | 001-43515 | 261486518 | 34 | 443190 | ||
| 2026-10-23 | S-8 | S-8 | 0001628280-26-067067 | 333-299617 | 261482522 | 33 | 284647 | 1 | 1 | |
| 2026-10-23 | 424B4 | 424B4 | 0001628280-26-067048 | 333-299300 | 261482322 | 33 | 13807511 | |||
| 2026-10-22 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-003321 | 333-299300 | 261479833 | 33 | 1777 | ||
| 2026-10-22 | 3 | 3 | 0001193125-26-429267 | 4866 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10232026_011010.xml | 0001231919-26-001493 | 22673 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111005.xml | 0001698766-26-000006 | 3922 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111021.xml | 0001422304-26-000003 | 10925 | ||||||
| 2026-10-22 | 3 | 3 | 0001193125-26-429196 | 16254 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111049.xml | 0001379344-26-000009 | 12960 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111008.xml | 0001182471-26-000005 | 13204 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111030.xml | 0002159567-26-000003 | 13680 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111001.xml | 0002159565-26-000003 | 15544 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111009.xml | 0002010805-26-000005 | 12254 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111039.xml | 0002050422-26-000015 | 10910 | ||||||
| 2026-10-22 | 3 | xslF345X06/form3-10222026_111057.xml | 0001750495-26-000005 | 15685 | ||||||
| 2026-10-22 | S-1MEF | S-1MEF | 0001628280-26-066940 | 333-299592 | 261479607 | 33 | 272747 | 1 | 1 | |
| 2026-10-22 | CERT | LYCA_8A_Cert_0001806540.pdf | 0001354457-26-001015 | 001-43515 | 261478716 | 34 | 564263 | |||
| 2026-10-20 | 8-A12B | 8-A12B | 0001628280-26-066384 | 001-43515 | 261470438 | 34 | 22128 | |||
| 2026-10-20 | S-1/A | S-1/A | 0001628280-26-066381 | 333-299300 | 261470436 | 33 | 15842344 | 1 | 1 | |
| 2026-10-05 | S-1 | DRS/A | 0001628280-26-064973 | 333-299300 | 261440888 | 33 | 17104956 | 1 | 1 | |
| 2026-08-27 | DRS/A | filename1.htm | 0001806540-26-000005 | 377-09537 | 261331295 | 33 | 10683570 | |||
| 2026-07-02 | DRS | filename1.htm | 0001628279-26-000815 | 377-09537 | 261150889 | 33 | 12286852 | |||
| 2026-06-25 | D | xslFormDX01/primary_doc.xml | 06b | 0001806540-26-000001 | 021-588627 | 261120687 | 33 | 10594 | ||
| 2024-05-23 | D | xslFormDX01/primary_doc.xml | 06b | 0001806540-24-000002 | 021-514102 | 24976967 | 33 | 10586 | ||
| 2021-09-16 | D | xslFormDX01/primary_doc.xml | 06b | 0001806540-21-000003 | 021-413559 | 211256763 | 33 | 9730 | ||
| 2020-03-17 | D | xslFormDX01/primary_doc.xml | 06b | 0001806540-20-000001 | 021-363038 | 20720402 | 33 | 8108 |
One latest value per concept from companyfacts (5 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ffd | NetFeeAmt | NetFeeAmt | USD | 11,225.56 | 2026-10-23 | S-8 | 2026-10-23 | 0001628280-26-067067 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 11,225.56 | 2026-10-23 | S-8 | 2026-10-23 | 0001628280-26-067067 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 129.03M | 2026-10-23 | S-8 | 2026-10-23 | 0001628280-26-067067 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-23 | S-8 | 2026-10-23 | 0001628280-26-067067 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-10-22 | S-1MEF | 2026-10-22 | 0001628280-26-066940 |